CTS-1027 is primarily investigated for its potential therapeutic applications in treating chronic inflammatory diseases and viral infections. It has shown promise in modulating the immune response, particularly in conditions like hepatitis C, where it helps reduce inflammation and liver damage. Additionally, CTS-1027 is being studied for its role in inhibiting metalloproteinases, which are enzymes involved in tissue degradation and inflammation, making it a candidate for treating autoimmune disorders and certain cancers. Its ability to regulate immune activity positions it as a potential treatment for diseases where immune system dysregulation plays a key role.